Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11545359 | 0.93 | DGKA (0.45) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL3517702 | 0.91 | — | — | |
| SCHEMBL30309890 | 0.88 | ADRA2A (0.46) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL28466792 | 0.88 | FNTA (0.44) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL3517136 | 0.84 | TSHR (0.44) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL3521471 | 0.84 | TSHR (0.44) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL209595 | 0.83 | ADRA2A (0.50) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL98980 | 0.83 | DGKA (0.46) | ADRA2AADRA1AFNTAFNTBMAPT | |
| SCHEMBL10682247 | 0.81 | DGKA (0.69) | MAPTDGKADNM1TSHRHTR2C | |
| SCHEMBL6911602 | 0.81 | DGKA (0.69) | MAPTDGKADNM1TSHRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190902-A1 | ALKYLTIN SULFANYL ESTER THIOLS | CHEMTURA CORPORATION (US) | 2010-07-29 | — | — | US | claimed |
| US-20100190902-A1 | ALKYLTIN SULFANYL ESTER THIOLS | CHEMTURA CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190902-A1 | ALKYLTIN SULFANYL ESTER THIOLS | SULT1E1, SULT1A1, TST | ADRA2A 2709/4885ADRA1A 1760/4885FNTA 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.